fludarabine has been researched along with Abnormalities, Autosome in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Boubaya, M; Bravetti, C; Chapiro, E; Davi, F; Dehgane, L; Doualle, C; Garnier, D; Grange, B; Jondreville, L; Lerner, LK; Nguyen-Khac, F; Roos-Weil, D; Smagghe, L; Susin, SA; Tournilhac, O | 1 |
| Appleby, N; Cahill, MR; Crotty, G; Enright, H; Hayat, A; Hennessy, B; Hodgson, A; Kelly, J; Leahy, M; O'Brien, D; O'Dwyer, M; O'Leary, H; Parker, I; Quinn, FM; Scott, K; Smyth, L; Vandenberghe, EA | 1 |
| Li, H; Li, ZJ; Liu, HM; Lü, R; Qiu, LG; Wang, TY; Xiong, WJ; Yi, SH; Yu, Z | 1 |
| Brychtova, Y; Brzobohata, A; Doubek, M; Mayer, J; Mraz, M; Panovska, A; Pavlova, S; Pospisilova, S; Skuhrova Francova, H; Spunarova, M; Tom, N; Trbusek, M | 1 |
| Busch, R; Cramer, P; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kandler, G; Pflug, N; Reinart, N; Stilgenbauer, S; Weit, N; Westermann, A; Winkler, D | 1 |
| Ariel, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shapiro, M; Shvidel, L; Tadmor, T | 1 |
| Appelbaum, FR; Bennett, JM; Byrd, JC; Claus, R; Dewald, GW; Flinn, IW; Grever, MR; Gribben, JG; Hussein, MA; Jelinek, DF; Larson, RA; Lozanski, A; Lozanski, G; Lucas, DM; Moore, DF; Neuberg, DS; Paietta, EM; Plass, C; Ruppert, AS; Tallman, MS | 1 |
| Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L | 1 |
| de Campos-Nebel, M; González-Cid, M; Larripa, I | 1 |
| Karasawa, M | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Sinsabaugh, C | 1 |
| Andrieux, J; Baranger, L; Barin, C; Bilhou-Nabera, C; Blons, H; Callet-Bauchu, E; Chapiro, E; Chevret, S; Chiesa, J; Daudignon, A; Eclache, V; Gachard, N; Grelier, A; Henry, C; Lambert, J; Leblondon, V; Lejeune, J; Luquet, I; Merle-Beral, H; Mossafa, H; Mould, S; Mozziconacci, MJ; Mugneret, F; Nguyen-Khac, F; Owen, R; Penther, D; Struski, S; Terre, C; Veronese, L | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Fil'chenkov, AA; Nesina, IP; Smirnova, IA; Zavelevich, MP | 1 |
| Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F | 1 |
| Agirre, X; Calasanz, MJ; Giraldo, P; Larráyoz, MJ; Odero, MD; Rubio-Felix, D; Rubio-Martinez, A; Valgañón, M | 1 |
| Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ | 1 |
| Califano, C; Celentano, M; D'Amico, MR; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pollio, F | 1 |
| Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Juliusson, G | 1 |
| del Giglio, A; Keating, M; O'Brien, S | 1 |
| Benner, A; Bentz, M; Cabot, G; Coy, J; Diehl, D; Döhner, H; Fischer, K; Galle, PR; Hansen, K; Hunstein, W; Lichter, P; Poustka, A; Schlenk, R; Stilgenbauer, S; Volkmann, M | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Kipps, TJ | 1 |
| Aul, C; Gattermann, N; Germing, U; Misgeld, E | 1 |
| Cuello, MT; Fundia, AF; González-Cid, M; Larripa, I | 1 |
| Marlton, P; McCarthy, C; Taylor, K | 1 |
| Beran, M; Childs, C; Huh, Y; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Schachner, J | 1 |
4 review(s) available for fludarabine and Abnormalities, Autosome
| Article | Year |
|---|---|
[Chronic lymphocytic leukemia and the related disorders].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chromosome Aberrations; Gene Rearrangement; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Recombination, Genetic; Rituximab; Time Factors; Vidarabine | 2008 |
Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Cladribine; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1994 |
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Chlorambucil; Chromosome Aberrations; Cladribine; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Vidarabine | 1995 |
Chronic lymphocytic leukemia.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; CD79 Antigens; Chromosome Aberrations; Chromosomes, Human; Cladribine; Combined Modality Therapy; Cytokines; Female; Genes, Immunoglobulin; Genes, p53; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Stem Cells; Prognosis; Risk Factors; Vidarabine | 2000 |
9 trial(s) available for fludarabine and Abnormalities, Autosome
| Article | Year |
|---|---|
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2018 |
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mitoxantrone; Proto-Oncogene Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2013 |
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Mutational Analysis; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2015 |
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotype; Male; Middle Aged; Prognosis; Prospective Studies; Trisomy; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Vidarabine | 2002 |
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 7; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; DNA Damage; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Remission Induction; Rituximab; Time Factors; Vidarabine | 2005 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Chromosome Aberrations; Chromosome Disorders; Female; Humans; Immunoglobulin M; Karyotyping; Leukemia, Prolymphocytic; Male; Middle Aged; Prednisone; Remission Induction; Vidarabine | 1991 |
17 other study(ies) available for fludarabine and Abnormalities, Autosome
| Article | Year |
|---|---|
del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
Topics: Chromosome Aberrations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Prognosis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Vidarabine | 2023 |
Efficacy of Rituximab for Patients with Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2017 |
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Rituximab; Survival Rate; Vidarabine | 2019 |
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells.
Topics: Adult; Androstadienes; Animals; Benzaldehydes; Cell Line; Cell Proliferation; Cell Survival; CHO Cells; Chromosome Aberrations; Cricetinae; Cricetulus; DNA; DNA Breaks, Double-Stranded; DNA Ligases; DNA Repair; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fibroblasts; Foreskin; Humans; Lymphocytes; Male; Mitotic Index; S Phase; Vidarabine; Wortmannin | 2008 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 20; Female; Flow Cytometry; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2011 |
Effects of etoposide and fludarabine in subtoxic doses on karyotype of human malignant lymphoid Namalwa cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatids; Chromosome Aberrations; Chromosomes; Culture Media; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Humans; Karyotyping; Lymphoma; Mutagens; Vidarabine | 2003 |
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Genes, p53; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Treatment Outcome; Vidarabine | 2005 |
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Drug Administration Schedule; Humans; Male; Monosomy; Myelodysplastic Syndromes; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Stem Cell Transplantation; Vidarabine | 2006 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Chromosome Aberrations; Chromosomes, Human, Pair 17; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Pentostatin; Polymorphism, Single-Stranded Conformational; Survival Rate; Vidarabine | 1995 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2001 |
Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cells, Cultured; Chromosome Aberrations; DNA Fragmentation; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Idarubicin; Lymphocytes; Mutagens; Vidarabine | 2002 |
Fludarabine-induced cytogenetic remission in prolymphocytic leukemia.
Topics: Aged; Chromosome Aberrations; Chromosome Disorders; Humans; Karyotyping; Leukemia, Prolymphocytic; Male; Vidarabine | 1992 |